Clinical trial
A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04585815 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Pfizer
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- November 10, 2020
- Completion date
- October 29, 2024
- Enrollment
- 34 (actual)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.